Email Updates

Search form

You are here

Browse and Order Resources

In the Report, we argue that the state of HIV prevention data collection in 2016 is poor. One part of the solution lies in the adoption of “HIV Prevention Data Dashboards”. This tracking tool could bring the same specificity and accountability to non-ART prevention services that the “treatment cascade” of diagnosis, initiation, retention and virologic suppression does for antiretrovirals for people living with HIV.

July 2016
AVAC
AVAC Report

The theme of this year’s World AIDS Day captures the spirit: Hands Up for HIV Prevention. At AVAC, we’re delighted to see the focus on this critical area of the global response. Our new issue of Px Wire provides specifics on some hot topics for advocacy before, on and after World AIDS Day.

October 2016
AVAC
Px Wire

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.

October 2016
The Resource Tracking for HIV Prevention R&D Working Group
AVAC
IAVI
Report/Issue Brief

PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.

August 2016
AVAC
Infographic

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

May 2016
AVAC
Infographic

The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Simple, easy-to-use microbicides would help these individuals take control of their own health—while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.

July 2016
AVAC
Infographic

In AVAC Report 2014/15: HIV Prevention on the Line, we take on the current state of global targets for the AIDS response, looking beyond pithy slogans to explore what’s in place and what’s not in terms of targets, resources and action to begin to end the AIDS epidemic. We also provide concise updates and calls to action on key prevention interventions including AIDS vaccines, voluntary medical male circumcision, microbicides, PrEP, and hormonal contraception use and HIV risk.

February 2015
AVAC
AVAC Report

A handbook designed to guide the user through various communication scenarios. The handbook offers tips and strategies to navigating difficult scenarios that may occur throughout the clinical trial process. It also offers suggestions on routine scenarios such as result dissemination and training staff and spokespersons.

February 2014
FHI 360
Handbook/Manual
Training Material

A comprehensive 2012 report from civil society about the state of voluntary medical male circumcision in Africa. Includes priority recommendations and in-depth discussion of factors influencing national scale-up efforts.  

July 2012
AVAC
National Empowerment Network of People Living with HIV/AIDS in Kenya
Sonke Gender Justice Network
Uganda Network of AIDS Service Organizations
Report/Issue Brief

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials. This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

June 2011
AVAC
UNAIDS
Handbook/Manual
Training Material

Pages